Literature DB >> 22152782

In search of psychosis biomarkers in high-risk populations: is the mismatch negativity the one we've been waiting for?

Aysenil Belger1, Gunes H Yucel, Franc C L Donkers.   

Abstract

Entities:  

Mesh：

Year:  2012        PMID： 22152782     DOI： 10.1016/j.biopsych.2011.11.009

Source DB:  PubMed          Journal:  Biol Psychiatry        ISSN： 0006-3223            Impact factor:   13.382


× No keyword cloud information.
  20 in total

1.  Attenuated Mismatch Negativity in Attenuated Psychosis Syndrome Predicts Psychosis: Can Galantamine-Memantine Combination Prevent Psychosis?

Authors:  Maju Mathew Koola
Journal:  Mol Neuropsychiatry       Date:  2018-06-07

2.  Mismatch negativity is a breakthrough biomarker for understanding and treating psychotic disorders.

Authors:  Gregory A Light; Risto Näätänen
Journal:  Proc Natl Acad Sci U S A       Date:  2013-08-30       Impact factor: 11.205

3.  Neurophysiological biomarkers informing the clinical neuroscience of schizophrenia: mismatch negativity and prepulse inhibition of startle.

Authors:  Gregory A Light; Neal R Swerdlow
Journal:  Curr Top Behav Neurosci       Date:  2014

Review 4.  Future clinical uses of neurophysiological biomarkers to predict and monitor treatment response for schizophrenia.

Authors:  Gregory A Light; Neal R Swerdlow
Journal:  Ann N Y Acad Sci       Date:  2015-03-09       Impact factor: 5.691

5.  Auditory mismatch impairments are characterized by core neural dysfunctions in schizophrenia.

Authors:  Arnim Johannes Gaebler; Klaus Mathiak; Jan Willem Koten; Andrea Anna König; Yury Koush; David Weyer; Conny Depner; Simeon Matentzoglu; James Christopher Edgar; Klaus Willmes; Mikhail Zvyagintsev
Journal:  Brain       Date:  2015-03-04       Impact factor: 13.501

6.  Pitch and Duration Mismatch Negativity and Premorbid Intellect in the First Hospitalized Schizophrenia Spectrum.

Authors:  Dean F Salisbury; Nicola R Polizzotto; Paul G Nestor; Sarah M Haigh; Justine Koehler; Robert W McCarley
Journal:  Schizophr Bull       Date:  2017-03-01       Impact factor: 9.306

7.  Validation of mismatch negativity and P3a for use in multi-site studies of schizophrenia: characterization of demographic, clinical, cognitive, and functional correlates in COGS-2.

Authors:  Gregory A Light; Neal R Swerdlow; Michael L Thomas; Monica E Calkins; Michael F Green; Tiffany A Greenwood; Raquel E Gur; Ruben C Gur; Laura C Lazzeroni; Keith H Nuechterlein; Marlena Pela; Allen D Radant; Larry J Seidman; Richard F Sharp; Larry J Siever; Jeremy M Silverman; Joyce Sprock; William S Stone; Catherine A Sugar; Debby W Tsuang; Ming T Tsuang; David L Braff; Bruce I Turetsky
Journal:  Schizophr Res       Date:  2014-10-23       Impact factor: 4.939

8.  Fronto-parietal and temporal brain dysfunction in depression: A fMRI investigation of auditory mismatch processing.

Authors:  Jana Zweerings; Mikhail Zvyagintsev; Bruce I Turetsky; Martin Klasen; Andrea A König; Erik Roecher; Arnim J Gaebler; Klaus Mathiak
Journal:  Hum Brain Mapp       Date:  2019-05-12       Impact factor: 5.038

9.  Using biomarkers to inform diagnosis, guide treatments and track response to interventions in psychotic illnesses.

Authors:  Veronica B Perez; Neal R Swerdlow; David L Braff; Risto Näätänen; Gregory A Light
Journal:  Biomark Med       Date:  2014       Impact factor: 2.851

10.  Demand and modality of directed attention modulate "pre-attentive" sensory processes in schizophrenia patients and nonpsychiatric controls.

Authors:  Anthony J Rissling; Sung-Hyouk Park; Jared W Young; Michelle B Rissling; Catherine A Sugar; Joyce Sprock; Daniel J Mathias; Marlena Pela; Richard F Sharp; David L Braff; Gregory A Light
Journal:  Schizophr Res       Date:  2013-03-11       Impact factor: 4.939
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.